Kintara Therapeutics
Vancouver
About Kintara Therapeutics
Kintara Pharmaceuticals, Inc. engages in developing and commercializing cancer therapies in orphan and other cancer indications for the treatment of patients failing modern targeted or biologic therapy. The company’s principal product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which is in clinical trials stage for the treatment of refractory glioblastoma multiforme, a form of brain cancer. Kintara Pharmaceuticals, Inc. also has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the development of VAL-083 used in treating chronic myelogenous leukemia and lung cancer. The company was founded in 2010 and is headquartered in Vancouver, Canada.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $132.8M
- Funding stage: M&A
- Last round: Grant (Jun 2023)
- Ticker: nasdaq:DMPI
- Website: kintara.com
- Phone: 604-629-5989
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/kintara-therapeutics-167612 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.